Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 142Stomach Neoplasms 104Carcinoma, Non-Small-Cell Lung 87Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Melanoma 59Esophageal Neoplasms 57Ovarian Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasms 43Carcinoma, Renal Cell 43Triple Negative Breast Neoplasms 39Neoplasm Metastasis 37Lung Neoplasms 36Breast Neoplasms 36Uterine Cervical Neoplasms 35Cholangiocarcinoma 35Esophageal Squamous Cell Carcinoma 33Head and Neck Neoplasms 29Endometrial Neoplasms 29Biliary Tract Neoplasms 26Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Colonic Neoplasms 23Small Cell Lung Carcinoma 20Prostatic Neoplasms 17Liver Neoplasms 17Adenocarcinoma Of Esophagus 15Adenocarcinoma 15

Interventions

pembrolizumab 1enzalutamide 1bintrafusp alfa protein, human 1Sorafenib 1LY-2157299 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × pembrolizumab × Gastrointestinal × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡